BioWorld MedTech

Feb. 29, 2016

Elite French investors pump fresh $55 million into artificial heart

PARIS — To fund its ramp-up to market, artificial heart maker Paris-based Carmat SA raised €50 million ($55 million) through a reserved capital increase put together by a cluster of elite French institutional investors. Read More

Spectranetics hopeful for a stellar year, fueled by Stellarex DCB

OA trials numerous but endpoints tricky as stakeholders search for another way

International Stroke Conference tPA costs and their impact on AIS therapies addressed at meeting

Panel says a heavy hand will impede use of NGS in oncology

Other News to Note

Appointments & Advancements

Keeping you up to date on recent developments in Neurology

Today's news in brief

BioWorld

BioWorld briefs for Jan 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 16, 2026.

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Businesswoman pressing dollar sign on touchscreen

JPM 2026: Year kicks off with biopharma Q4 revenue and guidance

BioWorld

It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...